Tadalafil side effects, danger, risks, interactions with medications

Tadalafil is a medication used for male impotence.

Likelihood of Tadalafil-associated Adverse Events in Integrated Multiclinical Trial Database: Classification Tree Analysis in Men With Erectile Dysfunction.
Urology. 2009 Feb 2. Brock G, Glina S, Moncada I, Watts S, Xu L, Wolka A, Kopernicky V. Department of Surgery, Division of Urology, St. Joseph's Health Care London, University of Western Ontario, London, Ontario, Canada.
To identify the patient demographic factors, comorbidities, and concomitant medications associated with a change in the likelihood of tadalafil-associated side events in men with impotence. Pooled safety data were analyzed from 3488 tadalafil treated men who participated in 21 placebo-controlled clinical trials of tadalafil taken as needed or once daily. Three categories of tadalafil side effects were defined: vasodilatory (headache, flushing, nasal congestion, nasopharyngitis, and dizziness); musculoskeletal (back pain and myalgia); and gastrointestinal (dyspepsia). Of the 3488 tadalafil treated patients, 973 (28%) had any vasodilatory, musculoskeletal, and/or gastrointestinal tadalafil side effects. The patient characteristics associated with a change in the likelihood of any tadalafil side effects were diabetes, geographic region, and age. The patient characteristics associated with a change in the likelihood of a vasodilatory tadalafil side effects included antihypertensive medication use, geographic region, and height, with several additional splits occurring along these primary and secondary nodes. No patient characteristics associated with a change in the likelihood of musculoskeletal or gastrointestinal side effects were identified owing to the limitation of a relatively low incidence of these types of side effects. The findings from classification and regression tree analyses could help physicians to better understand some of the associations between patient characteristics and the tolerability of phosphodiesterase type 5 inhibitors and could contribute to improved patient outcomes, satisfaction, treatment seeking, and treatment persistence.